Home > Healthcare > Medical Devices > Diagnostic Devices > Breast Cancer Liquid Biopsy Market

Breast Cancer Liquid Biopsy Market Trends

Report ID: GMI12188
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Breast Cancer Liquid Biopsy Market Trends

The increasing prevalence of breast cancer, recognized as the second most common cancer type, has substantially fuelled market demand for advanced diagnostic techniques. As cancer cases rise, there is an escalating need for early and targeted diagnostic solutions. This uptick in incidence, coupled with advancements in diagnostic technology, has created a growing demand for non-invasive diagnostic methods that facilitate early detection and effective treatment planning.

For instance, according to the International Agency for Research on Cancer (IARC) 2022 report, female breast cancer is the most common among 20 million new cancer cases worldwide, representing 11.6% of all cases. This increasing incidence has created a significant potential patient population with a pressing need for reliable diagnostic techniques and treatments, thereby bolstering market demand. Consequently, there is a surging need for non-invasive techniques such as liquid biopsy, which are driving market growth.
Additionally, the rising requirement for ongoing screening and diagnostics has significantly expanded the market, as repeat biopsy tests are essential for effective treatment management.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global breast cancer liquid biopsy industry was valued at USD 305.9 million in 2023 and is estimated to grow at a 22.6% CAGR from 2024 to 2032, driven by the rising incidence of breast cancer and advancements in diagnostic technologies.

The cfDNA segment dominated the global market and is anticipated to grow at a 22.5% CAGR over the forecast period due to its non-invasive nature and ability to provide real-time insights into tumor dynamics.

U.S. breast cancer liquid biopsy industry accounted for USD 133.3 million in 2023 and is anticipated to grow significantly during the forecast period, supported by advanced healthcare infrastructure and substantial R&D investments.

Key players in the industry include Datar Cancer Genetics, Epic Sciences, F. Hoffmann-La Roche, Genes2me, Illumina, Menarini Silicon Biosystems, Myriad Genetics, OncoDNA, and QIAGEN.